Understand your drug better and increase success rates in early clinical development

Immuneed helps innovative biotechs advance their preclinical projects by providing a better understanding of their drug candidates. We are experts in immunology and pharmaceutical development and have experience working with a broad range of biotherapeutics. Immuneed offers services ranging from selecting the right drug candidate to evaluating infusion risks. Our expertise paired with our unique model of fresh, circulating human blood enables us to capture a breadth of the immune response not possible elsewhere. Immuneed's loop model is applicable during drug discovery and development – from screening of drug candidates to early clinical development. All our solutions are flexible and we tailor study design and project to address your specific needs

 

 

Contact Us!

Are you interested in our services to assess toxicity and/or efficacy of your drug candidate?

Get in touch to find out how we can help you!

I'm interested in






In order for us to get in touch with you we must store some of your data on our servers. Checking the 'I consent' box indicates that you have read our privacy policy which outlines how we process, protect and manage your data, and that you consent to us storing it in accordance with this policy.

I consent

NEWS

Immuneed AB and Danish biotech company ImmuMap ApS have entered into a collaboration agreement - Uppsala 2019-09-10 Swedish biotech company Immuneed AB and Danish biotech company ImmuMap ApS have entered into a collaboration agreement, the signing of which was announced today. The agreement combines our two companies’ scientific expertise, specialized laboratory platforms and unique methodological know-how, enabling us to offer even better tailored solutions for our customers. ImmuMap’s long-term mode-of-action …
Immuneed will be attending the Nordic Life Science Days 2019. - We’re looking forward to seeing new and familiar faces at the NLS days 2019. Drop by booth 54 to meet us and CTC Clinical Trials Consultants. Justyna Leja-Jarblad, COO of Immuneed, will give a talk on Sep 12. What? An innovative approach to prepare biopharmaceuticals for clinical development. The focus lies on preclinical safety assessment, …
Pills Is your drug safe enough to enter the clinic? - Why choosing the right assay could make or break your first-in-man trial. In GLP toxicology studies, it’s an obvious choice to select a physiologically relevant animal model but when completing the safety assessment with in-vitro assays, researchers tend to get puzzled, often thinking that no results means “go”. The toxicity of monoclonal antibodies (mAbs) can …